{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04535999",
            "orgStudyIdInfo": {
                "id": "834149"
            },
            "organization": {
                "fullName": "University of Pennsylvania",
                "class": "OTHER"
            },
            "briefTitle": "Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)",
            "officialTitle": "Phase IV Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "open-label-study-of-the-effects-of-secukinumab-on-nail-psoriasis-and-non-invasive-measures-of-enthesitis-phase-iv"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-08-27",
            "studyFirstSubmitQcDate": "2020-08-27",
            "studyFirstPostDateStruct": {
                "date": "2020-09-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Pennsylvania",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Novartis",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.",
            "detailedDescription": "This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. This is a single arm trial - all patients will receive the study drug. We will examine time to response and different methods of defining nail disease response."
        },
        "conditionsModule": {
            "conditions": [
                "Psoriasis"
            ],
            "keywords": [
                "Psoriasis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Intervention-Secukinumab",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE",
                    "maskingDescription": "Open Label"
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Open Label",
                    "type": "EXPERIMENTAL",
                    "description": "Secukinumab",
                    "interventionNames": [
                        "Drug: Secukinumab Auto-Injector"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Secukinumab Auto-Injector",
                    "description": "300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)",
                    "armGroupLabels": [
                        "Open Label"
                    ],
                    "otherNames": [
                        "Cosentyx"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "NAPSI",
                    "description": "Nail Psoriasis Severity Index (NAPSI): NAPSI is the most comprehensive nail assessment used in clinical trials. The fingernail is divided into four quadrants. For each quadrant, 1 point is assigned for a nail matrix abnormality and 1 point for a nail bed abnormality allowing for a total of 8 points per nail. 0-80 total points possible with a higher score corresponding to a worse outcome.",
                    "timeFrame": "Baseline to 24 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PASI",
                    "description": "Psoriasis Area Severity Index (PASI): Four assessments for each of four body areas (head, trunk, upper extremities, and lower extremities) are provided. The assessments are erythema, induration, and scale (each assessed as 0-4 using a standardized scale), and the number of palms/percentage of each area is categorized (0 = 0%, 1 = less than 10%, 2 = 10%-29%, 3 = 30%-40%, 4 = 50%-69%, 5 = 70%-89%, and 6 = 90%-100%). The scale is 0 to 72 with a higher score corresponding to a worse outcome.",
                    "timeFrame": "Baseline to 24 Weeks"
                },
                {
                    "measure": "Physician Global Assessment of Nail Disease",
                    "description": "Physician Global Assessment of Nail Disease. Scale of 0-100 with higher score corresponding to a worse outcome.",
                    "timeFrame": "Baseline to 24 Weeks"
                },
                {
                    "measure": "DLQI",
                    "description": "Dermatology Life Quality Index (DLQI):\n\nThere are a total of 10 questions and each question is scored on a four-point Likert scale:\n\nVery much = 3 A lot = 2 A little = 1 Not at all = 0 Not relevant = 0 Question unanswered = 0\n\nThe DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.",
                    "timeFrame": "Baseline to 24 Weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Active psoriatic nail disease defined as a Minimum 4 or more fingernails OR NAPSI\\>20\n* Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist\n* Age 18-85\n\nExclusion Criteria:\n\n* History of IL-17 inhibitor use (other therapies including TNF inhibitors or non- biologics DMARDS in the past are acceptable)\n* Inflammatory bowel disease\n* Metal implants or other concerns for use of MRI\n* Active infection\n* Patients may have a history of self-reported psoriatic arthritis but may not have active PsA at the time of screening.\n* We will exclude patients with onychomyosis of the fingernails on clippings",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sarah Gillespie, MS",
                    "role": "CONTACT",
                    "phone": "2156141840",
                    "email": "sarah.hopkins@pennmedicine.upenn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Alexis Ogdie-Beatty, MD",
                    "affiliation": "University of Pennsylvania",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Hospital at the University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Gillespie, MS",
                            "role": "CONTACT",
                            "phone": "215-614-1840",
                            "email": "sarah.hopkins@pennmedicine.upenn.edu"
                        },
                        {
                            "name": "Alexis Ogdie-Beatty, MD, MSCE",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011565",
                    "term": "Psoriasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017444",
                    "term": "Skin Diseases, Papulosquamous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14422",
                    "name": "Psoriasis",
                    "asFound": "Psoriasis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19713",
                    "name": "Skin Diseases, Papulosquamous",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}